• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Resilience Announces Long-Term Financing of up to $825 Million to Accelerate CDMO Strategy

    10/29/25 3:05:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance
    Get the next $TROW alert in real time by email

    New Capital from Oak Hill Advisors to Drive Investment in Go-Forward Manufacturing Operations

    National Resilience ("Resilience"), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced long-term debt financing of up to $825 million from Oak Hill Advisors ("OHA") to strengthen its balance sheet and fuel its growth plans. This new capital will enable Resilience to accelerate its CDMO business strategy and invest in its go-forward manufacturing operations anchored in Cincinnati and Toronto.

    This financing underscores Resilience's critical role as a CDMO manufacturing sterile drugs at scale and on shore. OHA brings more than three decades of investment experience and a proven track record of supporting growth in the life sciences sector. Resilience remains focused on high-growth segments in the biopharmaceutical market to advance cell-based medicines, primarily biologics, and aseptic drug product operations. The company is in the process of expanding its Cincinnati facility into one of the largest, most advanced sterile injectable and device assembly and packaging operations in North America.

    William S. Marth, President and Chief Executive Officer of Resilience, said, "This financing is a pivotal step forward for our enterprise and positions us well to advance our ongoing transformation efforts backed by favorable industry tailwinds in the CDMO sector. This new capital will support the continued buildout of our core manufacturing operations and enable us to serve our customers with stability and excellence into the future, particularly at a time when pharmaceutical onshoring is a national priority. Partnering with OHA and our supportive long-time shareholders, we are confident that Resilience now has the right focus, footprint and financial profile to capitalize on the exciting strategic growth opportunities ahead."

    "We believe Resilience is uniquely positioned to scale its advanced manufacturing capabilities and meet the increasing demand for complex medicines," said Joe Goldschmid, Managing Director at OHA. "Our investment reflects conviction in the company's leadership team, strategic positioning and ability to generate long-term value in a sector undergoing rapid transformation. We look forward to supporting Resilience as it expands its footprint and strengthens its role in the global biomanufacturing ecosystem."

    The financing includes a $600 million first lien commitment from OHA. The initial tranche of $525 million is expected to be funded later in the fourth quarter, with the remainder of the financing in subsequent years as needed. Financing is subject to satisfaction of customary conditions.

    In addition to obtaining the new term loan, Resilience has successfully resolved the lease obligations related to its underutilized sites, further optimizing its balance sheet.

    Jefferies LLC is serving as financial advisor and Kirkland & Ellis LLP is serving as legal counsel to Resilience on the financing transaction.

    About Resilience

    Resilience is a North American contract development and manufacturing organization (CDMO) focused on delivering high-quality, scalable manufacturing solutions for advanced therapies. With capabilities spanning biologics drug substance, cell-based therapies, and aseptic drug product manufacturing for both small and large molecules, Resilience partners with leading biopharma companies to bring complex medicines to market faster and more reliably. The company is building a streamlined, high-performance network designed to meet the evolving needs of clinical and commercial-stage innovators. For more information, visit https://resilience.com/ and follow us on social media: Resilience on LinkedIn.

    About Oak Hill Advisors

    Oak Hill Advisors (OHA) is a leading global credit-focused alternative asset manager with over 30 years of investment experience. OHA works with institutions and individuals and seeks to deliver a consistent track record of attractive risk-adjusted returns. The firm has approximately $98 billion in assets under management (AUM) across credit strategies, including private credit, distressed and special situation investments, high yield bonds, leveraged loans and collateralized loan obligations as of June 30, 2025. Additional information on OHA's AUM calculation methodology can be found on the OHA website. OHA's emphasis on long-term partnerships with companies, sponsors and other partners allows for the provision of customized credit solutions across market cycles.

    With over 420 experienced professionals across six global offices, OHA brings a collaborative approach to offering investors a single platform to meet their diverse credit needs. OHA is the private markets platform of T. Rowe Price Group, Inc. (NASDAQ – GS: TROW). For more information, please visit www.oakhilladvisors.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251028436418/en/

    Media Contacts

    For Resilience:

    Kekst CNC

    [email protected]

    Catherine Hanley

    Vice President, Corporate Communications

    Resilience

    [email protected]

    For OHA:

    Natalie Harvard

    Head of Investor Relations & Partner

    (212) 326-1505

    [email protected]

    Get the next $TROW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TROW

    DatePrice TargetRatingAnalyst
    10/3/2025$108.00Market Perform
    BMO Capital Markets
    9/12/2024$109.00Equal Weight
    Wells Fargo
    8/27/2024$99.00Underweight
    Barclays
    4/11/2024$106.00 → $120.00Underperform → Mkt Perform
    Keefe Bruyette
    4/8/2024$92.00 → $114.00Sell → Hold
    TD Cowen
    1/8/2024$95.00 → $105.00Equal Weight → Underweight
    Wells Fargo
    1/4/2024$88.00Underperform
    TD Cowen
    10/31/2023$100.00 → $95.00Sell → Neutral
    Citigroup
    More analyst ratings

    $TROW
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by T. Rowe Price Group Inc.

    SCHEDULE 13G/A - PRICE T ROWE GROUP INC (0001113169) (Subject)

    3/27/26 1:19:17 PM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    SEC Form DEFA14A filed by T. Rowe Price Group Inc.

    DEFA14A - PRICE T ROWE GROUP INC (0001113169) (Filer)

    3/17/26 6:20:55 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    SEC Form DEF 14A filed by T. Rowe Price Group Inc.

    DEF 14A - PRICE T ROWE GROUP INC (0001113169) (Filer)

    3/17/26 6:16:34 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    $TROW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BMO Capital Markets initiated coverage on T. Rowe Price with a new price target

    BMO Capital Markets initiated coverage of T. Rowe Price with a rating of Market Perform and set a new price target of $108.00

    10/3/25 8:45:55 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    Wells Fargo initiated coverage on T. Rowe Price with a new price target

    Wells Fargo initiated coverage of T. Rowe Price with a rating of Equal Weight and set a new price target of $109.00

    9/12/24 9:14:34 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    Barclays initiated coverage on T. Rowe Price with a new price target

    Barclays initiated coverage of T. Rowe Price with a rating of Underweight and set a new price target of $99.00

    8/27/24 7:37:56 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    $TROW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wilson Alan D

    4 - PRICE T ROWE GROUP INC (0001113169) (Issuer)

    3/31/26 12:33:45 PM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 4 filed by Wijnberg Sandra S

    4 - PRICE T ROWE GROUP INC (0001113169) (Issuer)

    3/31/26 12:33:28 PM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 4 filed by Verma Richard R.

    4 - PRICE T ROWE GROUP INC (0001113169) (Issuer)

    3/31/26 12:33:10 PM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    $TROW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NEW T. ROWE PRICE PODCAST EPISODE EXAMINES THE FUTURE OF AI AND HUMAN ADVANTAGE

    A conversation on AI, curiosity, and the skills that endure BALTIMORE, April 2, 2026 /PRNewswire/ -- T. Rowe Price, a global investment management firm and leader in retirement, announces a new episode of "The Angle from T. Rowe Price," its investment-themed podcast focused on the ideas and events influencing financial markets. In the episode, "Humans vs. Machines: David Rowan on Curiosity, Creativity, and the Future of AI," Justin Thomson, head of the T. Rowe Price Investment Institute, sits down with David Rowan, technology journalist, investor, and founding editor-in-chief of

    4/2/26 9:30:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    T. ROWE PRICE NAMES BILL CASHEL AS HEAD OF ALTERNATIVES FOR ITS WEALTH CHANNEL

    New leadership role strengthens intermediary engagement and advances firm's growing alternatives offeringBALTIMORE, March 31, 2026 /PRNewswire/ -- T. Rowe Price, a global investment management firm and a leader in retirement, announced today that Bill Cashel has joined the firm as Head of Alternatives for U.S. Wealth. The appointment comes at a time of notable development within T. Rowe Price's alternatives business, as the firm continues to expand its private markets offerings and the alternatives team that supports them. In his new role, Cashel will work closely with sales tea

    3/31/26 10:00:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    T. ROWE PRICE EXPLORES LEADERSHIP, TRANSFORMATION, AND THE FUTURE OF MOBILITY WITH FORD CEO JIM FARLEY

    Newest episode of "The Angle" from T. Rowe Price features a candid conversation on strategic reinvention, electrification realities, and leading with urgency and purposeBALTIMORE, March 25, 2026 /PRNewswire/ -- T. Rowe Price, a global investment management firm and a leader in retirement, announced the latest episode of "The Angle from T. Rowe Price," an investment-themed podcast focused on the forces shaping financial markets and the leaders navigating them. In the newest episode, host Eric Veiel, Head of Global Investments and Chief Investment Officer for T. Rowe Price, sits d

    3/25/26 9:00:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    $TROW
    Financials

    Live finance-specific insights

    View All

    T. ROWE PRICE GROUP REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS

    BALTIMORE, Feb. 4, 2026 /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW), announced its financial results for the fourth quarter and full year 2025. The earnings release can be found on the firm's website at troweprice.com/newsroom. Chair, CEO, and President Rob Sharps and Chief Financial Officer Jen Dardis will provide an update on business performance, review financial results, and answer questions on a webcast today from 8:00 - 8:45 AM (Eastern Time). To access the webcast or to obtain dial-in instructions to ask a question, please visit investors.troweprice.com.

    2/4/26 7:00:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    T. ROWE PRICE GROUP REPORTS THIRD QUARTER 2025 RESULTS

    BALTIMORE, Oct. 31, 2025 /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW) announced its financial results for the third quarter of 2025. The earnings release can be found on the firm's website at troweprice.com/newsroom. Chair, Chief Executive Officer, and President Rob Sharps and Chief Financial Officer Jen Dardis will provide an update on business performance, review financial results, and answer questions on a webcast today from 8:00 - 8:45 AM ET. To access the webcast or to obtain dial-in instructions to ask a question, please visit investors.troweprice.com. Sup

    10/31/25 7:00:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    T. ROWE PRICE GROUP, INC., DECLARES QUARTERLY DIVIDEND

    BALTIMORE, Oct. 28, 2025 /PRNewswire/ -- T. Rowe Price Group (NASDAQ-GS: TROW), a global asset management firm and a leader in retirement, announced today that its Board of Directors has declared a quarterly dividend of $1.27 per share payable on December 30, 2025, to stockholders of record as of the close of business on December 15, 2025. ABOUT T. ROWE PRICE T. Rowe Price (NASDAQ-GS: TROW) is a leading global asset management firm entrusted with managing $1.77 trillion in client assets as of September 30, 2025, about two-thirds of which are retirement-related. Renowned for ov

    10/28/25 12:20:00 PM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    $TROW
    Leadership Updates

    Live Leadership Updates

    View All

    Longeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of Directors

    BALTIMORE, March 20, 2026 (GLOBE NEWSWIRE) -- Longeviti Neuro Solutions, a neurotechnology company developing advanced implantable and AI-enabled solutions for neurological health including the ClearFit AI™, the first Acoustic Brain Interface (ABI)™, today announced the appointment of Robert W. Sharps, Chief Executive Officer and President of T. Rowe Price Group, Inc. (NASDAQ:TROW), to its Board of Directors. Sharps brings three decades of leadership experience in global asset management, capital markets, corporate governance, and strategic growth. As CEO and the Chairman of the Board of T. Rowe Price, he oversees one of the world's leading investment firms, managing more than $1.5 trilli

    3/20/26 10:48:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    STEPH JACKSON TO RETIRE FROM T. ROWE PRICE INVESTMENT MANAGEMENT

    Steven Krichbaum named successor and new head of TRPIM in 2027 BALTIMORE, Jan. 22, 2026 /PRNewswire/ -- T. Rowe Price announced today a planned leadership transition within its T. Rowe Price Investment Management division (TRPIM), as Steph Jackson, who currently serves as head of TRPIM and is a member of the Management Committee, will be retiring at the end of 2026. Jackson's tenure at T. Rowe Price has been marked by impactful leadership and a steadfast commitment to clients, associates, and community. Since joining T. Rowe Price in 2007, Jackson has held influential roles,

    1/22/26 8:45:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $TROW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by T. Rowe Price Group Inc. (Amendment)

    SC 13G/A - PRICE T ROWE GROUP INC (0001113169) (Subject)

    2/13/24 4:55:53 PM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G/A filed by T. Rowe Price Group Inc. (Amendment)

    SC 13G/A - PRICE T ROWE GROUP INC (0001113169) (Subject)

    1/29/24 12:09:07 PM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G/A filed by T. Rowe Price Group Inc. (Amendment)

    SC 13G/A - PRICE T ROWE GROUP INC (0001113169) (Subject)

    2/10/23 12:26:32 PM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance